Wisconsin is currently home to 1261 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT06056830
Recruiting
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Prostate Cancer, Prostatic Neoplasms
Register for Updates
Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy
NCT05615844
Recruiting
The Beads vs Vac trial is a multi-centre randomized controlled trial of 312 participants with a severe open tibia fracture requiring multiple irrigation and debridement surgeries. Eligible participants will be randomized to receive either an antibiotic bead pouch or negative pressure wound therapy (NPWT) for their temporary open fracture wound management. Outcomes will be assessed at 6 weeks, 3 months, and 6 months post-surgery. The primary outcome will be a composite outcome to evaluate clinica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Open tíbia Fracture
Register for Updates
Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction
NCT05223322
Recruiting
Very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. Much of what has been learned about molecular pathways regulating vascular endothelial function has been established by logical expansion of knowledge obtained through experimental studies (e.g., discovery of endothelium-derived relaxing factor/nitric oxide). Within the last 10 years technological advancements of -omics approaches, such as RNA-sequencing an... Read More
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/29/2025
Locations: Medical College of Wisconsin, Wauwatosa, Wisconsin
Conditions: Breast Cancer
Register for Updates
Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
NCT03971591
Recruiting
This study will examine the efficacy of Men Moving Forward (MMF), a four-month community-based lifestyle intervention designed for AA PC survivors. MMF is rooted in the evidence-based Moving Forward lifestyle intervention developed with and for AA breast cancer survivors. This intervention was adapted in collaboration with AA PC survivors. It will offer twice weekly sessions aimed at supporting adherence to the ACS nutrition and physical activity guidelines to promote improved body composition (... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Prostate Cancer
Register for Updates
Improving Show Rates in Dental Care Settings Serving Underserved Populations
NCT06581250
Recruiting
The goal of this study is to compare different no-show interventions in dental clinics serving underserved populations. The main question it seeks to answer is * How do different no-show intervention methods compare in reducing no-shows? Participants will be asked to * Implement different interventions * Report a limited set of data to researchers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Dental Care
Register for Updates
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
NCT06158854
Recruiting
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of AL amyloidosis. This study in broken into... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Wisconsin Medical Center /ID# 255836, Milwaukee, Wisconsin
Conditions: Immunoglobulin Light Chain (AL) Amyloidosis
Register for Updates
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140
Recruiting
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. A substudy will enroll participants from Arms A and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Gundersen Health System, W. Salem, Wisconsin
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Research Site, Madison, Wisconsin
Conditions: Breast Cancer
Register for Updates
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
NCT05373017
Recruiting
This study will evaluate the usefulness of the Urgent and Emergency Surgery (UES) Delirium Recovery Model. It is hypothesized that the cognitive, physical and psychological recovery of older UES delirium survivors will be improved through the use of the DANE Recovery Model. Participants can expect to be on the study for 18 months.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/28/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Delirium
Register for Updates
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
NCT04919122
Recruiting
ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in the United States, including both community and academic treatment settings.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/28/2025
Locations: The Medical College of Wisconsin, Inc., Milwaukee, Wisconsin
Conditions: Metastatic Renal Cell Carcinoma
Register for Updates
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Select Advanced Solid Tumors
Register for Updates
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Clinical Trial Site, Milwaukee, Wisconsin
Conditions: Generalized Myasthenia Gravis
Register for Updates